Overview

Safety and Tolerability of RNS60 Given by IV to Healthy Subjects

Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety and tolerability of RNS60 administered intravenously to healthy subjects. 12 subjects will receive RNS60 or placebo at three escalating rates for 48 hours for each rate.
Phase:
Phase 1
Details
Lead Sponsor:
Revalesio Corporation
Treatments:
RNS60